In-Patient Study In Schizophrenic Patients

Summary

This study is a placebo-controlled study to assess the safety and tolerability of a novel antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight days. Assessments include blood sampling to determine drug concentrations, psychiatric assessments while under treatment, and movement assessments to evaluate potential side effects.

Timeline

Start

2004-09

Primary completion

—

Completion

—

Drugs

Indications